George Sands, Nisha Bansal and Wolfgang C. Winkelmayer/LinkedIn
Jun 5, 2026, 18:32
George Sands: A Thoughtful Editorial on Low-Dose Rivaroxaban in Advanced CKD
George Sands, Ex-Senior Medical Director of Pfizer, Principal of Sands Collaborative, shared a post on LinkedIn about a recent article by Nisha Bansal and Wolfgang C. Winkelmayer, published in JAMA, adding:
“Sharing a very thoughtful editorial by Bansal and Winkelmyer about a trial in CKD patients, stage 4 and 5.
This randomized study is very helpful. This patient population is very challenging to randomize in clinical trials.
This was a placebo-controlled trial vs low-dose rivaroxaban.
The editorial sums it all up beautifully; approximately 5-minute read.”
Title: Rivaroxaban for Cardiovascular Disease Prevention in Chronic Kidney Disease
Authors: Nisha Bansal, Wolfgang C. Winkelmayer
Stay updated on all sceintific advances with Hemostasis Today.
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026